Legal & General Group’s Arcutis Biotherapeutics ARQT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.56M | Buy |
111,603
+4,025
| +4% | +$56.4K | ﹤0.01% | 2063 |
|
|
2025
Q1 | $1.68M | Sell |
107,578
-249
| -0.2% | -$3.89K | ﹤0.01% | 1991 |
|
|
2024
Q4 | $1.5M | Sell |
107,827
-149
| -0.1% | -$2.08K | ﹤0.01% | 2099 |
|
|
2024
Q3 | $1M | Buy |
107,976
+3,585
| +3% | +$33.3K | ﹤0.01% | 2234 |
|
|
2024
Q2 | $971K | Buy |
104,391
+96,075
| +1,155% | +$893K | ﹤0.01% | 2210 |
|
|
2024
Q1 | $82.4K | Sell |
8,316
-226
| -3% | -$2.24K | ﹤0.01% | 2746 |
|
|
2023
Q4 | $27.6K | Sell |
8,542
-35,221
| -80% | -$114K | ﹤0.01% | 2913 |
|
|
2023
Q3 | $232K | Buy |
43,763
+7,579
| +21% | +$40.2K | ﹤0.01% | 2688 |
|
|
2023
Q2 | $345K | Buy |
36,184
+19,148
| +112% | +$183K | ﹤0.01% | 2580 |
|
|
2023
Q1 | $187K | Buy |
17,036
+1,100
| +7% | +$12.1K | ﹤0.01% | 2610 |
|
|
2022
Q4 | $236K | Buy |
15,936
+723
| +5% | +$10.7K | ﹤0.01% | 2548 |
|
|
2022
Q3 | $291K | Buy |
15,213
+3,409
| +29% | +$65.2K | ﹤0.01% | 2483 |
|
|
2022
Q2 | $252K | Buy |
11,804
+3,072
| +35% | +$65.6K | ﹤0.01% | 2553 |
|
|
2022
Q1 | $168K | Hold |
8,732
| – | – | ﹤0.01% | 2728 |
|
|
2021
Q4 | $181K | Hold |
8,732
| – | – | ﹤0.01% | 2762 |
|
|
2021
Q3 | $209K | Buy |
8,732
+4,949
| +131% | +$118K | ﹤0.01% | 2676 |
|
|
2021
Q2 | $103K | Sell |
3,783
-550
| -13% | -$15K | ﹤0.01% | 2721 |
|
|
2021
Q1 | $125K | Buy |
4,333
+1,919
| +79% | +$55.4K | ﹤0.01% | 2559 |
|
|
2020
Q4 | $68K | Buy |
2,414
+257
| +12% | +$7.24K | ﹤0.01% | 2704 |
|
|
2020
Q3 | $63K | Buy |
2,157
+586
| +37% | +$17.1K | ﹤0.01% | 2611 |
|
|
2020
Q2 | $48K | Sell |
1,571
-46
| -3% | -$1.41K | ﹤0.01% | 2739 |
|
|
2020
Q1 | $48K | Buy |
+1,617
| New | +$48K | ﹤0.01% | 2597 |
|